Compare MED & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MED | MGNX |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 115.8M |
| IPO Year | 1996 | 2013 |
| Metric | MED | MGNX |
|---|---|---|
| Price | $10.42 | $1.88 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $12.00 | $3.20 |
| AVG Volume (30 Days) | 246.2K | ★ 533.9K |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | $149,962,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 155.26 |
| 52 Week Low | $10.10 | $0.99 |
| 52 Week High | $15.37 | $2.49 |
| Indicator | MED | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 38.24 | 57.06 |
| Support Level | $10.19 | $1.62 |
| Resistance Level | $12.21 | $1.97 |
| Average True Range (ATR) | 0.39 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 28.07 | 67.47 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.